FDA Grants Interchangeable Designation to Fresenius Kabi’s Biosimilars Conexxence and Bomyntra (denosumab-bnht)

Nov 3, 2025 - 10:00
 0  1
LAKE ZURICH, Ill., October 29, 2025 – Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the U.S. Food and Drug Administration (FDA)...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0